# Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

> **NCT07684898** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Gensciences Biopharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** FRSW107

## Key facts

- **NCT ID:** NCT07684898
- **Lead sponsor:** Hangzhou Gensciences Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-12
- **Primary completion:** 2027-03-09
- **Final completion:** 2027-06-21
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684898, "Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*